A new brain area affected by 3,4-methylenedioxymethamphetamine: A microdialysis-biotelemetry study

European Journal of Pharmacology
Khalid BenamarMartin W Adler

Abstract

The widespread abuse of 3,4-methylenedioxymethamphetamine (MDMA) has intensified the need to learn more about this drug (e.g. its effects, its mechanism of action, brain areas affected). MDMA-induced hyperthermia is a severe physiological event not only because it can produce severe adverse consequences in human as well as experimental animals, but also because it plays a major role in determining the severity of the long-term MDMA-induced neurotoxicity that occurs. However, the effects of MDMA on the preoptic anterior hypothalamus, the main brain area responsible for control of body temperature, are still unknown. In vivo microdialysis-biotelemetry and pharmacological testing were used to determine whether the preoptic anterior hypothalamus is among the brain areas affected by MDMA by investigating the role of the dopamine neurotransmitter system. We examined the effect of a hyperthermic dose of MDMA on the extracellular level of dopamine in the preoptic anterior hypothalamus, and whether this effect is related to the acute hyperthermic response. The administration of a hyperthermic dose of MDMA (20 mg/kg) is accompanied by an increase in the extracellular level of dopamine in the preoptic anterior hypothalamus. Both the hyper...Continue Reading

References

Jul 11, 1991·Pharmacology, Biochemistry, and Behavior·B GoughR R Holson
Jul 23, 1984·Brain Research·I M Scott, J A Boulant
Jan 12, 1999·Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology·M YasumatsuY Aihara
May 11, 2002·Life Sciences·Khalid BenamarMartin W Adler
Sep 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Khalid BenamarMartin W Adler
Aug 13, 2004·Brain Research·Khalid BenamarMartin W Adler
Oct 1, 2004·The Journal of Pharmacology and Experimental Therapeutics·Altaf S DarveshGary A Gudelsky

❮ Previous
Next ❯

Citations

Nov 22, 2013·Neurotoxicity Research·N GranadoR Moratalla
Mar 5, 2014·Toxicological Sciences : an Official Journal of the Society of Toxicology·Joseph M HerndonTerrence J Monks
Dec 28, 2010·Neuroscience and Biobehavioral Reviews·Susan Schenk
Oct 5, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Allison A FeducciaChristine L Duvauchelle
Oct 13, 2015·Progress in Neurobiology·Rosario MoratallaMicaela Morelli
Oct 1, 2013·Pharmacology Research & Perspectives·Laura E HalpinBryan K Yamamoto
Sep 20, 2011·Drug and Alcohol Dependence·A C Parrott
Oct 19, 2010·European Journal of Pharmacology·Natacha Vanattou-SaïfoudineUNKNOWN Neuropsychopharmacology Research Group
Dec 29, 2020·Journal of Neurochemistry·Rubén García-CabrerizoJohn F Cryan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.